Schnell to conduct Phase I trial for biosimilar drug

Published: 2011-07-13 06:57:00

Updated: 2011-07-13 06:57:00

Schnell Biopharmaceutical said it will carry out its Phase 1 clinical trial for its arthritis biosimilar after recent approval from the Korea Food and Drug Administration.

Schnell plans to develop and commercialize the drug candidate named GS 071 together with Japan’s Nichi-Iko Pharmaceuticals...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK